Join us for a conversation with Saharsh, Vice Chairman and Managing Director of Neuland. After 18 years with the company, including building its CDMO business, he’s stepping into the CEO role and shares his immediate priorities: closer client–team collaboration, timely delivery of major R&D and facility investments, balancing growth between generic APIs and an expanding CDMO business, and strengthening supply‑chain resilience.

14 0

0 0

We recently spoke with Jagruti Patel from Lonza about a major new facility acquisition and its customer impact. Jagruti explains the Vacaville, CA acquisition, which adds substantial mammalian stainless‑steel capacity, will support US onshoring and dual sourcing, help onboard more customers, and expand Lonza’s end‑to‑end lifecycle and drug‑product offerings.

0 0

Meet Omar Wahab, Head of Fire Processing, Lonza Bioscience. He highlights Lonza’s 30-year cell culture media legacy, the new TheraPEAK platform for AAV/HEK workflows, an FDA-approved cytokine supplement used in 130+ trials.
He also outlines Lonza’s innovation approach: strong internal R&D, partnerships with CDMOs, and recent inorganic growth through the acquisition of Redberry.

Watch the full interview to hear more about these advances and what they mean for the future of cell therapy manufacturing.

0 0

1 0

Welcome to our video interview featuring Alessandra Basso, Global Sales and Marketing Director of Sunresin Life Science, and Dr. Rob Schoevaart, Managing Director and co-founder of Chiralvision.

In this discussion, they will highlight their collaboration, combining Sunresin’s resin expertise with ChiralVision’s biocatalysis skills to develop innovative immobilised enzyme technologies. Tune in as they explore the potential for sustainability, the challenges ahead, and their shared vision for transforming the biocatalysis landscape for customers.

2 0

We recently spoke Lisa Stasi, about the ways Ecolab Life Sciences is helping life sciences companies navigate change management to drive operational excellence, compliance, and timely regulation implementation.

With this video, learn more about the digital solutions helping manufacturers keep pace.

0 0

In a recent video interview, Anil Kane, Executive Director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, introduces OSD Predict, a cutting-edge predictive modeling platform that aims to enhance the efficiency and speed of oral solid dose delivery. This innovative toolbox features multiple tools designed to revolutionize drug formulation and development, including advanced modeling for solubility, compaction simulations, and stability predictions.

OSD Predict streamlines the candidate selection process while minimizing trial and error, significantly shortening the timeline from Phase 1 to Phase 2 and beyond. By integrating AI and machine learning, this platform leverages extensive data for robust predictions, ultimately ensuring that effective medicines reach patients faster.

Don’t miss this great interview to learn more about how OSD Predict can transform drug development and create impactful benefits for the pharmaceutical industry.

2 0